Skip to the content

A shareholders meeting will be held on Thursday, September 17th 2020, from 12:00 to 12:30 to discuss and approve the following resolution:

- Resolution 1: The transfer of the intellectual property from Fibrofind Ltd to Fibrofind IP Ltd.

All shareholders are invited to contact Jeremy Domis ( to receive information about the location of the meeting.

Fibrofind demonstrates Hepion's CRV431 efficacy on IPF

In a new study ran for Hepion's Pharmaceuticals, Fibrofind demonstrate that Hepion's drug candidate, CRV431, first tested on Liver shows efficacy on idiopathic pulmonary fibrosis.

Meet Fibrofind at NASH Summit 2020

Jelena Mann and Lee Borthwick, respectively CEO and COO of Fibrofind will be present and present our Precision-Cut Slice technology at the 4th Annual NASH Summit

Fibrofind at Keystone Symposia on Fibrosis and Tissue Repair

From February 19-23, three of our directors attended Keystone Symposia on Fibrosis and Tissue Repair, with our COO, Dr. Lee Borthwick, presenting our Precision-Cut Slice technology

Read our publication on our PCLS Technology

Read our Precision-Cut Liver Slice technology paper published in Hepatology Journal

Hepion Pharaceutical: CRV431 shows great antifibrotic efficacy in PCLS study

​Hepion Pharmaceutical's NASH drug shows remarkable efficacy in a Precision-cut Liver slice Study on human tissue preformed by Fibrofind

Hepion Pharaceuticals - Nasdaq: +46% on positive NASH data

Great results on testing its CRV431 compound in a Fibrofind PCLS Study leads to impressive results on Hepion's value on the Nasdaq Stock Exchange